NCT05176080终止1 期
Study to Evaluate the Efficacy and Safety of Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- RP2D in phase Ib
研究概览
简要总结
The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer.
详细描述
This study would enroll patients with hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer, aimed to evaluate the efficacy and safety of treatment with famitinib combined with SHR6390 and endocrine therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Local recurrent or metastatic breast cancer unsuitable for chemotherapy, confirmed histologically.
- •HR-positive, HER2- negative breast cancer(according to 2018 ASCO/CAP HER2 test guideline).
- •Ib: Patients who received no more than 2 line of chemotherapy in advanced setting were recruited; II: Patients who had not received any chemotherapy and no more than 1 line of endocrine therapy.
- •18-75 years old.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0～
- •life expectancy is not less than 12 weeks.
- •at least one measurable lesion according to RECIST 1.
- •Absolute neutrophil count (ANC) ≥ 1.5×10^9/L, Platelets ≥90×10^9/L, Hemoglobin ≥ 90 g/L; Total bilirubin≤1.5 upper limit of normal (ULN)；Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)≤2.5×ULN (ALT and AST≤5×ULN if liver metastasis); blood urea nitrogen (BUN) and Creatinine (Cr)≤1.5×ULN
- •Left ventricular ejection fraction (LVEF) ≥ 50% and QTc≤470 ms
排除标准
- •Patients who received Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine kinase inhibitors (TKI); II: Patients who received fulvestrant, everolimus or cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor;
- •Ib: Patients who had symptomatic brain metastasis; II: Patients who had brain metastasis;
- •Patients unsuitable for endocrine therapy;
- •Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption.
- •Participated in other drug clinical trials within 4 weeks before admission
- •Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.
- •Active human immunodeficiency virus (HIV), hepatitis B or hepatitis C;
- •Has suffered from any heart disease
- •Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial
- •According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).
- •Moderate infection occurs within 4 weeks before the first administration (e.g. intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical criteria), fever（> 38.5 ℃） of unknown origin occurs during the screening period/before the first administration.
- •Researchers believe that patients are unsuitable for any other situation in this study.
研究组 & 干预措施
Treatment group
Experimental
Famitinib Plus SHR6390 and Endocrine therapy
干预措施: Famitinib (Drug)
Treatment group
Experimental
Famitinib Plus SHR6390 and Endocrine therapy
干预措施: SHR6390 (Drug)
Treatment group
Experimental
Famitinib Plus SHR6390 and Endocrine therapy
干预措施: Fulvestrant (Drug)
结局指标
主要结局
RP2D in phase Ib
时间窗: Up to 4 weeks
Recommended phase II dose (PR2D) in phase Ib
ORR in phase II
时间窗: up to 2 years
Objective response rate (ORR) by investigator in phase II
次要结局
- AE(up to 2 years)
- ORR in phase Ib(up to 2 years)
- PFS in phase II(up to 2 years)
- PFS in phase Ib(up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Famitinib Malate in HER2-negative Metastatic Breast CancerBreast NeoplasmsNCT01653574Fudan University28
终止
2 期
A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic SyndromeHypereosinophilic SyndromeNCT00171860Novartis Pharmaceuticals24
已完成
2 期
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.Leukemia, Nonlymphocytic, AcuteNCT00354146Johnson & Johnson Pharmaceutical Research & Development, L.L.C.252
已完成
2 期
Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 InhibitorsHypogonadismErectile DysfunctionNCT00415571QuatRx Pharmaceuticals Company72
已完成
2 期
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid TherapyHypogonadismChronic Obstructive Pulmonary DiseaseNCT01061970QuatRx Pharmaceuticals Company15